News
AGEN
12.01
-7.26%
-0.94
Agenus Price Target Maintained With a $40.00/Share by HC Wainwright & Co.
Dow Jones · 8h ago
HC Wainwright & Co. Reiterates Buy on Agenus, Maintains $40 Price Target
Benzinga · 8h ago
Health Care Sector Update for 05/07/2024: VNDA, LGND, AGEN, OSCR
NASDAQ · 8h ago
Agenus’s bot/bal: A Multifaceted Oncology Candidate Poised for Accelerated Approval and Market Expansion
TipRanks · 10h ago
AGEN Stock Earnings: Agenus Misses EPS, Misses Revenue for Q1 2024
Agenus reported results for the first quarter of 2024. Agenus reported earnings per share of -$3.04. The company reported revenue of $28.01 million. This was 28.69% worse than the analyst estimate for revenue of $39.27 million.
Investorplace · 10h ago
Agenus Inc reports results for the quarter ended in March - Earnings Summary
Agenus Inc reports results for the quarter ended in March. Revenue rose 22.3% to $28.01 million from a year ago. The company reported a quarterly adjusted loss of $3.04 per share. Agenus Inc shares had risen by 11.6% this quarter.
Reuters · 12h ago
Ligand Enters Into $100 Mln Royalty Financing Agreement With Agenus For BOT/BAL Clinical Dvpt.
NASDAQ · 13h ago
Agenus Inc. Quarterly Report: Condensed Consolidated Financial Statements for the Quarter Ended March 31, 2024
Press release · 13h ago
Ligand Pharmaceuticals and Agenus enter into royalty financing deal
Ligand Pharmaceuticals and Agenus enter into a royalty financing deal. LGND will get 18.75% of the future royalties for six of AGEN's clinical-stage partnered oncology programs. Ligand will also get a 2.625% royalty on future global net sales of BOT/BAL.
Seeking Alpha · 14h ago
Agenus Secures Strategic Finance Deal with Ligand
TipRanks · 15h ago
AGENUS INC - $100M ROYALTY FINANCING AGREEMENT WITH LIGAND ANNOUNCED
Reuters · 15h ago
*Agenus Ended 1Q With a Cash and Cash Equivalent Balance of $52.9M >AGEN
Dow Jones · 15h ago
Ligand And Agenus Enter Into $100M Royalty Financing Agreement
Capital infusion will support clinical development, confirmatory Phase 3 trial, and launch readiness activities. Ligand entitled to royalties and milestone payments on six Agenus-partnered programs. BOT/BAL Transaction allows for syndication of up to an additional $125 million in capital.
Benzinga · 15h ago
AGENUS INC - LIGAND WILL RECEIVE 18.75% OF FUTURE ROYALTIES,31.875% OF FUTURE MILESTONE PAYMENTS RELATED TO SIX OF CO'S PROGRAMS
Reuters · 15h ago
AGENUS - COMPANIES ALSO AGREED TO ALLOW AGENUS TO SYNDICATE UP TO AN ADDITIONAL $125 MLN, POTENTIALLY BRINGING TOTAL CAPITAL INFUSION UP TO $200 MLN
Reuters · 15h ago
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
Ligand Pharmaceuticals and Agenus Inc. Have entered into a royalty financing agreement to support the development of BOT/BAL. The agreement includes a $75 million payment to Ligand. Lig and will receive 18.75% of the future royalties for AgenUS’s six cancer programs. BOT-BAL has the potential to be a transformative treatment for cancer patients.
Barchart · 20h ago
Notable earnings before Tuesday's open
Major earnings expected before the bell on Tuesday include: BP p.l.c. (BP) The Walt Disney and Duke Energy are among major companies slated for release before Tuesday's open. Other companies with major earnings scheduled for release include: Datadog (DDOG) and Nikola.
Seeking Alpha · 1d ago
Weekly Report: what happened at AGEN last week (0429-0503)?
Weekly Report · 1d ago
Agenus Inc <AGEN.OQ> expected to post a loss of $2.83 a share - Earnings Preview
Agenus Inc expected to post a loss of $2.83 a share - Earnings Preview. The company is expected to report a 71.5% increase in quarterly revenue to $39.268 million. Average analyst rating on the shares is "strong buy"
Reuters · 4d ago
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA), Repligen (RGEN) and Agenus (AGEN)
TipRanks · 4d ago
More
Webull provides a variety of real-time AGEN stock news. You can receive the latest news about Agenus through multiple platforms. This information may help you make smarter investment decisions.
About AGEN
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.